To obtain a broadly based exposure to European equity markets., focusing on sectoral rather than country asset allocation.
Name | % Net Assets |
---|---|
Total | 4.5% |
Sanofi-Aventis | 2.9% |
Novartis | 2.8% |
Roche Holdings | 2.6% |
ENI | 2.6% |
Deutsche Telekom | 2.5% |
BNP Paribas | 2.5% |
UBS AG | 2.1% |
Telefonica | 2.0% |
ABM-Amro Holdings | 1.9% |
Key | % Net Assets |
---|---|
Total | 4.5% |
Sanofi-Aventis | 2.9% |
Novartis | 2.8% |
Roche Holdings | 2.6% |
Other | 87.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 365.80p |
Currency | GBP |
Change | -0.20p |
% | -0.05% |
YTD change | -6.50p |
YTD % | -1.75% |
Fund Inception | 01/03/1987 |
---|---|
Fund Manager | Stuart Fraser |
TER | - |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | n/a |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.13 |
You are here: research